Related Experiment Videos

Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising

Victor L Serebruany1, Alex I Malinin, James J Ferguson

  • 1HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA. heartdrug@aol.com

Fundamental & Clinical Pharmacology
|May 20, 2008
PubMed

Insights

Dual antiplatelet therapy significantly increases major and minor bleeding risks compared to single antiplatelet agents. This increased bleeding risk should be considered in long-term treatment strategies for vascular disease patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Antiplatelet drugs are crucial for survivors of vascular events and high-risk individuals.
  • Previous studies evaluated aspirin alone or in combination, but direct comparisons of bleeding risks between single and dual therapy are needed.

Purpose of the Study:

  • To compare the risks of bleeding associated with single versus dual antiplatelet therapy regimens.
  • To quantitate the bleeding risks in patients with prior occlusive vascular disease or high cardiovascular risk factors.

Main Methods:

  • Meta-analysis of 18 randomized trials published in English from 1988-2006.
  • Included trials with at least 1-month follow-up and data on bleeding complications.
  • Compiled data on patient characteristics, antiplatelet agents, and bleeding events (major, minor, fatal, intracranial).

Main Results:

  • Dual antiplatelet therapy significantly increased major bleeding risk (RR 1.47, CI 1.36-1.60) and minor bleeding risk (RR 1.56, CI 1.47-1.66) compared to single agent therapy.
  • No significant differences were found in fatal or intracranial bleeding, though confidence intervals were wide.
  • Patients on dual therapy experienced a 40-50% increase in major and minor bleeding risks.

Conclusions:

  • Dual antiplatelet therapy is associated with a substantial increase in major and minor bleeding events.
  • This excess bleeding risk, comparable to single antiplatelet agents versus placebo, must be weighed against therapeutic benefits.
  • Consideration of this risk is essential when selecting optimal long-term antiplatelet strategies for high-risk vascular patients.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...